Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 01.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | port is incorporated herein by reference. Item 5.02. Departure of Directors or Certain Officers; Election of Director |
| 01.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | orated by reference into this Item 3.02. Item 5.02. Notice of Delisting or Failure To Satisfy a Continued Listing Rule |
| 06.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | d in Item 304(a)(1)(v) of Regulation S-K). Item 5.02. Departure of Directors or Certain Officers; Election of Director |
| 03.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | esignations as directors, as further described in Item 5.02, in the form contained in Exhibit 10.1 (each, a “Settlement |
Stammdaten
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Unternehmen & Branche
| Name | TITAN PHARMACEUTICALS INC |
|---|---|
| Ticker | TTNP |
| CIK | 0000910267 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 3,1 Mio. USD |
| Beta | 1,38 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-06-30 | 10-Q | -689,000 | -0.65 | 3,051,000 | 2,788,000 | |
| 2025-03-31 | 10-Q | -563,000 | -0.62 | 2,156,000 | 1,877,000 | |
| 2024-12-31 | 10-K | -4,706,000 | -5.23 | 2,923,000 | 2,440,000 | |
| 2024-09-30 | 10-Q | -763,000 | -0.83 | 3,602,000 | 3,231,000 | |
| 2024-06-30 | 10-Q | -2,093,000 | -2.29 | 4,350,000 | 3,994,000 | |
| 2024-03-31 | 10-Q | -1,060,000 | -1.24 | 6,646,000 | 6,087,000 | |
| 2023-12-31 | 10-K | -5,569,000 | -7.41 | 8,086,000 | 6,642,000 | |
| 2023-09-30 | 10-Q | -338,000 | -0.45 | 9,999,000 | 8,133,000 | |
| 2023-06-30 | 10-Q | -1,586,000 | -2.11 | 812,000 | -1,034,000 | |
| 2023-03-31 | 10-Q | -1,675,000 | -2.23 | 2,168,000 | -312,000 | |
| 2022-12-31 | 10-K | -10,206,000 | -15.19 | 4,058,000 | 1,363,000 | |
| 2022-09-30 | 10-Q | -2,638,000 | -0.18 | 6,276,000 | 3,550,000 | |
| 2022-06-30 | 10-Q | -2,462,000 | -0.18 | 8,319,000 | 5,667,000 | |
| 2022-03-31 | 10-Q | -2,540,000 | -0.24 | 10,318,000 | 7,882,000 | |
| 2021-12-31 | 10-K | -8,776,000 | 7,994,000 | 5,138,000 | ||
| 2021-09-30 | 10-Q | -1,915,000 | -0.19 | 9,637,000 | 7,496,000 | |
| 2021-06-30 | 10-Q | -1,680,000 | 11,507,000 | 8,747,000 | ||
| 2021-03-31 | 10-Q | -2,641,000 | 13,824,000 | 9,980,000 | ||
| 2020-12-31 | 10-K | -18,242,000 | 8,087,000 | 3,532,000 | ||
| 2020-09-30 | 10-Q | -4,932,000 | 8,018,000 | -897,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.